72
Participants
Start Date
August 27, 2021
Primary Completion Date
December 24, 2024
Study Completion Date
April 9, 2025
MT-3921
Solution for infusion; Intravenous (IV)
Placebo
Solution for infusion; Intravenous (IV)
Carilion Clinic, Roanoke
Carolinas Rehabilitation, Charlotte
Augusta University, Augusta
Tallahassee Neurological Clinic, Tallahassee
University of Mississippi Medical Center, Jackson
University of Kentucky, Lexington
University of Cincinnati, Cincinnati
Spectrum Health, Grand Rapids
Medical College of Wisconsin - Froedtert Hospital, Milwaukee
Saint Louis University Hospital, St Louis
University of Nebraska Medical Center, Omaha
The University of Texas Health Science Center at San Antonio, San Antonio
Brooke Army Medical Center in San Antonio, Houston
University of California Irvine, Orange
Oregon Health and Science University - Center for Health & Healing, Portland
NSHA-Queen Elizabeth II Health Sciences Centre, Halifax
The Ottawa Hospital, Ottawa
Japan Organization of Occupational Health and Safety SPINAL INJURIES CENTER, Izuka-shi
Gifu University Hospital, Gifu
Hokkaido Spinal Cord Injury Center, Bibai-shi
Japanese Red Cross Kobe Hospital, Kobe
National Hospital Organization Kumamoto Medical Center, Kumamoto
Murayama Medical Center, Musashimurayama-shi
Lead Sponsor
Mitsubishi Tanabe Pharma America Inc.
INDUSTRY